Compare ADNT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | CRVS |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2016 | 2016 |
| Metric | ADNT | CRVS |
|---|---|---|
| Price | $19.33 | $12.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $25.41 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 796.9K | 661.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $17,439,000,000.00 | N/A |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | $48.21 | ★ N/A |
| Revenue Growth | ★ 7.56 | N/A |
| 52 Week Low | $17.68 | $5.64 |
| 52 Week High | $27.32 | $26.95 |
| Indicator | ADNT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 36.72 |
| Support Level | $18.11 | $12.76 |
| Resistance Level | $22.52 | $14.00 |
| Average True Range (ATR) | 0.79 | 0.56 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 31.33 | 10.78 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.